Form D · Pharmaceuticals
Aquestive Therapeutics, Inc.
Warren, NJ · CIK 0001398733
Offering snapshot reported May 9, 2018 · SEC filing
- Reported sold
- $9.06M Offering amount: $9.06M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $100 Reported outside-investor minimum
- First sale
- Apr 24, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 9, 2018 | Initial | $9,063,956 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-312010
Source: Form D, filed May 9, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Barber | Executive |
| Peter Boyd | Executive |
| Douglas Bratton | Director |
| Gregory Brown | Director |
| John Cochran | Director |
| Santo Costa | Director |
| Keith J Kendall | Director, Executive |
| John T Maxwell | Executive |
| James S Scibetta | Director |
| A. Mark Shobel | Director, Executive |
| Theresa Wood | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
30 Technology Drive South
Warren, NJ, 07059
Warren, NJ, 07059